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Summary Expression of both P-glycoprotein (P-gp) and mutant p53 have recently been reported to be
associated with poor prognosis of breast cancer. The expression of P-gp is associated in vitro and in vivo with
cross-resistance to several anti-cancer drugs. p53 plays a regulatory role in apoptosis, and mutant p53 has been
suggested to be involved in drug resistance. Interestingly, in vitro experiments have shown that mutant p53 can
activate the promoter of the MDRI gene, which encodes P-gp. We investigated whether p53 and P-gp are
simultaneously expressed in primary breast cancer cells and analysed the impact of the co-expression on
patients' prognosis. Immunohistochemistry was used to investigate P-gp expression (JSB-1, C219) and nuclear
p53 accumulation (DO-7) in 20 operable chemotherapy untreated and 30 locally advanced breast cancers
undergoing neoadjuvant chemotherapy with doxorubicin and cyclophosphamide. Double immunostaining
showed that P-gp expression and nuclear p53 accumulation often occur concomitantly in the same tumour
cells. A correlation between p53 and P-gp expression was found in all 50 breast cancers (P=0.003; Fisher's
exact test). P-gp expression, nuclear p53 accumulation, and co-expression of p53 and P-gp were more
frequently observed in locally advanced breast cancers than in operable breast cancers (P=0.0004; P=0.048;
P=0.002 respectively, Fisher's exact test). Co-expression of p53 and P-gp was the strongest prognostic factor
for shorter survival by multivariate analysis (P=0.004) in the group of locally advanced breast cancers
(univariate analysis: P=0.0007). Only 3 out of 13 samples sequentially taken before and after chemotherapy
displayed a change in P-gp or p53 staining. In conclusion, nuclear p53 accumulation is often associated with P-
gp expression in primary breast cancer, and simultaneous expression of p53 and P-gp is associated with shorter
survival in locally advanced breast cancer patients. Co-expression ofP-gp and mutant p53 belong to a series of
molecular events resulting in a more aggressive phenotype, drug resistance and poor prognosis.
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Although adjuvant chemotherapy improves survival of
radically resected breast cancer, approximately 50% of all
patients will eventually relapse (Harris et al., 1992; Early
Breast Cancer Trialists' Collaborative Group, 1992). Further-
more, despite a response rate of over 50% induced by
combination chemotherapy in advanced breast cancer,
relapse invariably occurs, which is progressively less sensitive
to treatment. Development of broad resistance to anti-cancer
agents is thought to be responsible for chemotherapy failures
in neoplasms such as breast cancer, which are initially rather
sensitive and later on become resistant to chemotherapy.
A well-defined type of cellular drug resistance is multidrug
resistance (MDR), which is mediated by P-glycoprotein
(P-gp) expression (van Kalken et al., 1991). MDR is an in
vitro phenomenon of tumour cells, becoming cross-resistant
to a broad variety of structurally unrelated, natural product
anti-cancer drugs (e.g. anthracyclines, epipodophyllotoxins,
vinca alkaloids, actinomycin D and paclitaxel), after having
been grown in the presence of one of them. P-gp is an
integral plasma membrane protein of 170 kDa, encoded by
the MDR] gene, and acts as an energy-dependent drug efflux
pump, thereby decreasing the intracellular drug concentration
(van Kalken et al., 1991). P-gp is expressed in several normal
human tissues, such as colon, kidney, adrenal gland and
capillaries of the brain and testis, and has been found in
many cancer types, with the highest expression in tumours
originating from tissues constitutively expressing P-gp (van
Kalken et al., 1991). Furthermore, P-gp expression has been
suggested to be associated with chemoresistance, and poor
prognosis in several malignancies, such as acute myeloid
leukaemia, neuroblastoma, childhood sarcoma and breast
cancer (van Kalken et al., 1991).
From a limited number of studies there is evidence that P-
gp might play a role in resistance to cytotoxic drugs used in
breast cancer (Sanfilippo et al., 1991, Keith et al., 1990;
Salmon et al., 1989; Verelle et al., 1991). A correlation has
been observed between P-gp expression in breast cancer cells
obtained from patients and in vitro resistance to doxorubicin
(Sanfilippo et al., 1991; Keith et al., 1990; Salmon et al.,
1989). Furthermore, a high P-gp expression in 17 locally
advanced breast cancer patients was associated with the lack
of response to neoadjuvant chemotherapy and a shorter
disease-free survival (Verelle et al., 1991).
The p53 tumour-suppressor gene regulates genomic
stability (Greenblatt et al., 1994), and inactivation of its
product by several mechanisms, including point mutation,
gene deletion, overexpression of mdm-2 and binding to
proteins encoded by DNA tumour viruses, is at present the
most common event identified in human cancers (Greenblatt
et al., 1994). Recently, in vitro experiments have demon-
strated that mutant p53 can stimulate the MDRI promoter
(Chin et al., 1992), and may be involved in chemoresistance,
as wild-type p53 is required for the efficient activation of
apoptosis following treatment with anticancer drugs (Lowe et
al., 1993, 1994). Most p53 mutations result in a non-
functional protein that accumulates in tumour cell nuclei
(Allred et al., 1993). Nuclear p53 accumulation has been
associated with shorter disease-free and overall survival in
node-negative (Allred et al., 1993; Thor et al., 1992) and
-positive (Thor et al., 1992) sporadic breast cancer, as well as
in hereditary breast cancer (Thor et al., 1992).
In this study we evaluated the relationship between P-gp
expression and nuclear accumulation of p53 protein in 20
operable primary breast cancers, and in 30 locally advanced
breast cancer patients, undergoing neoadjuvant chemother-
apy. We also analysed the effect of P-gp expression and
nuclear p53 accumulation on clinical outcome.
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Tumour material originating from 50 breast cancer patients
(20 primary operable, 30 locally advanced) was centralised at
the Department of Pathology, Free University Hospital, in
Amsterdam. Primary breast cancer specimens were formalin
fixed, paraffin embedded and snap frozen in liquid nitrogen
and stored at -70°C until use; most locally advanced breast
cancer specimens were formalin fixed, paraffin embedded
only.
Locally advanced breast cancer patients received high-dose
neoadjuvant chemotherapy with doxorubicin (75-90 mg m-2
every 3 weeks) and cyclophosphamide (0.75- 1 g m-2 every 3
weeks) with 250 pug m-2 day-' granulocyte-macrophage
colony-stimulating factor (GM-CSF) subcutaneously (s.c.)
(days 2- 11) (n = 24) or intravenously (n=6), followed by
mastectomy. Thirteen patients, referred from other institutes,
had had a diagnostic needle aspiration for cytology before
chemotherapy, and unfortunately no other material was
available from these patients to determine P-gp and p53
status before chemotherapy; for these patients only
mastectomy material after chemotherapy was available. In
four cases only tumour material biopsied before chemother-
apy was assessable, as one patient received only radiotherapy
after neoadjuvant chemotherapy, two patients had a
pathological complete remission of the primary tumour
(one patient had only a few tumour cells left in two axillary
lymph nodes), and one patient did not have enough tumour
cells left to evaluate staining results. In 13 cases sequential
tumour samples were obtained both before and after
neoadjuvant chemotherapy.
Follow-up information was available in all patients, but
one operable breast cancer patient was excluded from
survival analysis as she had developed contralateral breast
cancer.
In summary, there were 37 chemotherapy-naive patients,
of whom 20 with primary operable and 17 with locally
advanced breast cancer.
Immunohistochemistry
Cryostat sections (4 pm) and cytospin preparations were air
dried and fixed in acetone at room temperature before
staining. Formalin-fixed, paraffin-embedded tissue was
processed with a recently developed antigen retrieval
technique in order to achieve higher staining sensitivity (Shi
et al., 1991). P-gp expression was detected with two murine
monoclonal antibodies (MAbs), directed against different
epitopes of the molecule; C219 (ITK Diagnostics, Uithoorn,
Netherlands), and JSB-1, raised in our laboratory (Scheper et
al., 1988). C219 was diluted in phosphate-buffered saline
(PBS) (pH 7.4) plus 1% bovine serum albumin (used for
dilution of all reagents, unless stated otherwise) at 1:10 (final
concentration 10 pg ml-') for both paraffin and cryostat
sections. JSB-l in ascites was used at a 1:100 dilution for all
sections, unless stated otherwise. For all patients, p53 was
assessed in formalin-fixed, paraffin-embedded material with
murine MAb DO-7 (Dakopatts, Denmark), at a dilution of
1:500 (final concentration 0.19 pg ml-'). All slides were
incubated with normal rabbit serum 1:50 for 10 min and
subsequently incubated with the MAbs for 1 h at room
temperature (JSB-l, C219), or overnight at 4°C (DO-7).
Immunohisto/cytochemistry was performed with an avidin-
biotin complex (ABC) immunoperoxidase method (Vectas-
tain, ABC kit, Vector Laboratories, Burlinghame, CA, USA)
as described previously (van der Valk et al., 1990). For P-gp
detection in formalin-fixed, paraffin-embedded tissues the
second and third step of the ABC immunoperoxidase method
were repeated. Slides were developed in 0.05% 3,3'-
diaminobenzidine tetrahydrochloride dihydrate (Sigma, St
Louis, MO, USA) with 0.02% hydrogen peroxide in PBS,
rinsed in tap water, counterstained with haematoxylin,
dehydrated, cleared and mounted with DePex mounting
medium (Gurr, BDH Laboratory Supplies, Poole, UK).
Negative control slides were run in parallel, omitting the
primary antibody or substituting it with an irrelevant mouse
myeloma IgG MAb, isotype-matched for JSB-1. In addition,
cytospin preparations as well as formalin-fixed, paraffin-
embedded cell pellet sections of a chemosensitive human
epidermoid carcinoma cell line KB3-1 and of the multidrug-
resistant cell lines KB-ChR-8-5, 8226DOX4 (human myeloma)
and SW-1573/2R160 (non-small-cell lung carcinoma) served
as negative and positive controls respectively. These cell lines
were processed identically to the formalin-fixed, paraffin-
embedded tissues in our pathology department and were
included in each staining experiment. For p53 staining a
positive colorectal cancer specimen served as control.
Samples were scored for each MAb separately by two
independent investigators (SCL, PvdV), blinded to clinical
outcome. For JSB-1 and C219 one of three distinct staining
patterns was observed in all the samples examined: all
tumour cells negative; occasional staining of single cells
(< 5% positive cells); numerous positive tumour cells
(>20%) throughout the section. Only four cases had 10%
positive tumour cells. The same staining pattern has been
described by others (Schneider et al., 1989). Considering the
observed staining pattern of tumour cells, and in order to
minimise the risk of a false positivity, samples were
considered positive for each MAb only if >,20% of tumour
cells were stained. This cut-off value has also been reported
by other investigators (Schneider et al., 1989; Chan et al.,
1991). p53 was considered positive if at least one tumour cell
nucleus stained with DO-7, as reported by other investigators
(Schneider et al., 1989; Chan et al., 1991). In addition, results
were also analysed using the median expression of each
protein as cut-off value.
Co-expression of P-gp and p53 protein in the same tumour
cells was analysed using a double immunostaining technique
that combined the ABC (JSB-1; dilution 1:150) and the
alkaline phosphatase/monoclonal anti-alkaline phosphatase
(APAAP) method (Dakopatts, Denmark) (DO-7; dilution
1:300) (Mullink et al., 1986). Several controls were included
in each staining series: (1) mono-staining with each of the
MAbs with (a) the ABC method and (b) the APAAP method;
(2) double staining sequences in which one (first or second
primary MAb) or two (first and second primary MAbs) steps
were changed into (a) PBS and (b) isotype-matched,
irrelevant mouse MAb.
Statistical methods
Linear regression analysis and Pearson's test were used to
assess correlation between p53 protein accumulation and P-
gp expression. Furthermore, correlations between P-gp
expression, accumulation of p53 protein and clinical stage
were assessed by Fisher's exact test (two-tail). For the 13
cases with sequential sampling, P-gp and p53 status of
tumour material obtained before the start of neoadjuvant
chemotherapy were used. Survival analysis was performed
according to Kaplan-Meier (Kaplan and Meier, 1958).
Overall survival time was defined as the time between date
of start of neoadjuvant chemotherapy and date of last follow-
up or death from recurrent disease. Survival analysis for the
total group of chemotherapy-naive breast cancer patients was
performed (n = 36) (19 primary operable and 17 locally
advanced breast cancers), as well as for the locally advanced
breast cancers only (n = 26), in the latter case using P-gp and
p53 status after chemotherapy. Differences between survival
curves were analysed using the Mantel-Cox test (Mantel,
1966; Cox, 1972). The Cox regression model (Cox, 1972) was
used for multivariate analysis to assess the prognostic value
of clinical state, lymph node status, clinical T-value (tumour
diameter), and P-gp/p53 tumour status in the group of
chemotherapy-naive patients (P-value enter=0.10; P-value
remove=0.10). Multivariate analysis was also performed for
the locally advanced breast cancer group to assess the
prognostic value of P-gp expression, nuclear p53 accumula-p53 and MDR1 co-expression in breast cancer
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tion, P-gp +/p53 +tumour status (positive for both P-gp and
p53), and the presence of macroscopic tumour; positive
lymph nodes and a positive apical axillary lymph node after
neoadjuvant chemotherapy (P-value enter=0.10; P-value
remove=0.10). Tests were carried out with the BMDP
statistical package (Los Angeles, CA, USA).
Results
Co-expression ofp53 and Pgp
Concordance between C219 and JSB-1 staining was 78%
(P=0.0003). In our hands staining sensitivity was higher with
JSB-1, and because, unlike C219, JSB-1 is MDR1 specific, we
defined P-gp positivity as staining of >20% tumour cells
with JSB-1. We also analysed our data with the median
expression of JSB-1 (> 10%) and the median nuclear
accumulation of p53 (>0%) as cut-off values, which gave
exactly the same results. Remarkably, a significant correlation
between nuclear p53 accumulation and P-gp staining was
found [linear regression: n= 50; r=0.51; P < 0.001 (Pearson)
and Table I]. Double immunostaining revealed that p53 and
P-gp positivity often occur concomitantly in the same tumour
cells (Figure 1). In P-gp+/p53+ cases (median 90%/50%
positive tumour cells), p53 accumulation was present mainly
in P-gp-positive cells, whereas in five P-gp+/p53+ cases the
majority of tumour cells were P-gp only positive, with a
minority of tumour cells expressing both antigens. Further-
more, nine cases had only p53 accumulation, without any P-
gp expression.
In some samples, P-gp staining of desmoplastic stromal
cells was observed, without P-gp staining of tumour cells.
These samples were considered P-gp negative (Wishart et al.,
1990).
Table I Correlation between P-gp expression and nuclear accumu-
lation of p53 in the total group of breast cancers examined (n= 50)
P-gp expression
Tumour status' Negative Positive p
p53 negative 21 5
p53 positive 9 15 0.003
aFor the patients with sequential sampling (n= 13) tumour status
before the start ofneoadjuvant chemotherapy was used.
Figure 1 Double immunostaining of P-gp and p53 in 'a locally
advanced breast cancer before neoadjuvant chemotherapy. Co-
expression of both antigens is present in several tumour cells. P-
gp (JSB-1) is found on tumour cell membranes (brown); p53 (DO-
7) accumulation is present in nuclei (blue). Original magnification
lOOx.
Operable breast cancer vs locally advanced breast cancer
Table II summarises clinical and immunohistochemical
characteristics of the operable and locally advanced breast
cancer groups. Patients were significantly younger in the
locally advanced breast cancer group. Furthermore, locally
advanced breast cancers were more frequently P-gp and p53
positive than operable breast cancers, and also P-gp+/p53+
tumour status was more often observed in the locally
advanced breast cancer group.
Response to neoadjuvant chemotherapy and expression ofP-gp
andp53
Response rate of neoadjuvant chemotherapy was 100% (16
partial remissions, 14 clinical complete remissions), including
two pathological complete remissions and one pathological
complete remission of the primary tumour in the presence of
tumour cells in lymph nodes.
Five of ten patients with P-gp+/p53+ tumours before
neoadjuvant chemotherapy achieved a clinical complete
remission, and one a pathological complete remission of the
primary tumour, but this patient had few tumour cells still
visible in three axillary lymph nodes. These results indicate
that neoadjuvant chemotherapy was effective in determining
major responses regardless of the expression ofp53 and P-gp.
In 10 out of 13 patients, with tumour material available
both before and after neoadjuvant chemotherapy, P-gp and
p53 status remained unchanged. In three cases the following
was observed: patient A, P-gp +/p53 + -* P-gp +/p53 -; this
patient had no change in P-gp expression (90%-90%), and
only a minor change from a few p53-positive nuclei in
approximately 1000 tumour cells to no cells with nuclear p53
accumulation. This patient had no recurrence after a follow-
up of 51 months. Patient B, P-gp +/p53- -* P-gp +/p53 +;
this patient had a change in P-gp expression from 75% to
90%, and in nuclear p53 accumulation from 0% to 10%.
This patient died 17 months after diagnosis. Patient C,
P-gp+/p53+ -* Pgp-/p53+; this patient had a change in P-
gp expression from 90% to only a few positive cells in
approximately 1000 tumour cells examined, and a change in
nuclear p53 accumulation from 90% to 60%. This patient
remained recurrence-free with a follow-up of 23 months.
Although these changes could just reflect tumour hetero-
geneity, we cannot exclude the possibility that expression
patterns of a tumour might vary as a result of treatment.
Survival analysis
Survival of P-gp + /p53+ chemotherapy-naive patients (n = 11)
was significantly shorter than that ofthe other chemotherapy-
naive patients (n =25) (2 year survival 53% vs 95%; P=0.04).
One primary operable breast cancer patient was excluded from
survival analysis as this patient had developed contralateral
breast cancer. P-gp+/p53+ tumour status of chemotherapy-
naive patients remained a prognostic factor by multivariate
analysis, but only after clinical tumour diameter (T-value),
lymph node status and clinical stage. Survival of P-gp+/p53+
locally advanced breast cancer patients (n=11) was signifi-
cantly shorter than that of the other locally advanced breast
cancer patients (n = 15) (median survival 17 months vs median
not reached at 72 months; 2 year survival 0% vs 90%;
P=0.0007) (Figure 2). P-gp+/pS3 + tumour status appeared
the strongest prognostic factor by multivariate analysis
(P=0.004), and no other factor added prognostic value to
this parameter in the locally advanced breast cancer group.
Thisfinding would suggest that presence ofco-expression ofP-
gp and p53 is an independent prognostic factor inbreast cancer.
Discussion
Several biological markers have been identified in breast
cancer that appear to have prognostic importance (Harris etAe.,,& p53 and MDR1 co-expression in breast cancer
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Table II Differences in characteristics between operable breast cancer and locally advanced breast cancer patients
Operable breast cancer Locally advanced breast cancer
Patient and tumour characteristics n=20 n=30 P
Median age in years (range) 63 (44-86) 49 (31 -63) 0.008
Clinical stage
I-Ib 18 - ND'
IIIa+ b 2 30
Histological tumour type












P-gp positive 2 18 0.0004
p53 positive 6 18 0.048
P-gp+/p53+ 1 14 0.002
aNot enough tumour cells in subclavicular lymph node biopsy for classification, and pathological complete remission after chemotherapy.
bColloid carcinoma. cln three cases not enough tumour cells present to determine differentiation grade. dFor patients with sequential sampling
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Figure 2 Survival curves of locally advanced breast cancer
patients: P-gp +/p53 + tumours --- - -) vs the rest of the patients
in this group ( ).
al., 1992); among them expression of P-gp and accumulation
of p53 have been described previously as prognosticators of
poor survival. As expression of P-gp has recently been shown
to be activated by overexpression of p53 in vitro (Chin et al.,
1992) we investigated the correlation of expression of these
two genes in 50 primary breast cancers.
We found a higher expression of both P-gp and p53 in
locally advanced mammary tumours, as compared with
operable tumours. Locally advanced mammary carcinomas
are known to have a poorer prognosis than smaller tumours,
and the expression of P-gp and p53 might confer greater
aggressiveness. Higher expression of P-gp in locally advanced
breast cancer as compared with operable tumours has been
reported by other investigators (Schneider et al., 1994).
Nuclear accumulation of p53 has been associated with
younger age (Allred et al., 1993), which may explain the
higher frequency of p53 positivity in the locally advanced
breast cancer group, which had a lower median age than the
operable breast cancer group.
In our study, we observed that nuclear p53 accumulation
and P-gp expression were highly correlated, in fact 75% of P-
gp-positive patients were also p53 positive. Interestingly,
membranous and cytoplasmic P-gp staining was often seen
concomitantly with nuclear p53 staining in the same tumour
cells. Correlation of expression between p53 and P-gp
positivity has recently also been described in a group of
231 operable breast carcinomas, where 78% of P-gp-positive
samples were also positive for p53 (Charpin et al., 1994).
Remarkably, we observed that co-expression ofp53 and P-
gp identified a group of patients within the locally advanced
category, with a more aggressive phenotype, which had in
fact a much shorter survival (2 year survival 0% vs 90%;
P=0.0007) than the rest of the patients. This co-expression
was the strongest prognostic factor by multivariate analysis,
which suggests that presence of co-expression of P-gp and
p53 is an independent prognostic factor in breast cancer.
In contrast to results of Charpin et al. (1994) and ours, a
smaller study of 31 breast cancers failed to detect a
correlation between P-gp expression and p53 accumulation
(Schneider et al., 1994). In this study however, no cut-off
point for positivity of immunohistochemical staining was
given and a different antibody, the polyclonal antibody 1801
(PAb 1801), was used to detect nuclear p53 accumulation.
PAb 1801 has been reported to recognise mutant p53 less
often than DO-7 (Jacquemier et al., 1994); furthermore,
differences in fixation and staining techniques can also
significantly influence the results. It cannot be excluded,
however, that different sites of p53 mutations are involved in
different patient populations. The site of p53 mutation may
be important for the ability of the mutant p53 to stimulate
the MDR] promoter (Greenblatt et al., 1994; Chin et al.,
1992). The mutant human p53 cDNA used for in vitro
experiments harboured a substitution from arginine to
histidine at codon 175 (Chin et al., 1992), and this site is
., nnXp53 d Rl c - esusin. bId caner
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one of the hotspots for p53 point mutations in breast cancer
(Greenblatt et al., 1994). The accumulation ofp53 as assessed
by immunohistochemistry with several antibodies does not
appear to coincide always with the presence of p53 gene
mutations (Greenblatt et al., 1994). The correspondence is in
fact of approximately 70-80% (Greenblatt et al., 1994).
Given the high response rate of the locally advanced
mammary carcinomas and the small number of pathologi-
cally confirmed complete remissions, we could not establish
any correlation between expression of P-gp, accumulation of
p53 and response to chemotherapy. Absence ofwild-type p53
has been recently found to be associated with in vitro
resistance to 5FU, etoposide and doxorubicin (Lowe et al.,
1993), and transfection of wild-type p53 can restore
chemosensitiviy in a drug-resistant cell line (Fujiwara et al.,
1994).
Interestingly, of ten patients with P-gp+/p53+ tumours
before neoadjuvant chemotherapy, five achieved a clinical,
and one a pathological complete remission, which suggests
that P-gp/p53 positivity can partly be overcome by the
moderately high-dose chemotherapy used in our study
(Hoekman et al., 1991). Because we used tumour status
after neoadjuvant chemotherapy for survival analysis in the
locally advanced breast cancer group, one could hypothesise
that P-gp+/p53+ clones were selected by chemotherapy.
However, we could demonstrate that in the majority of
patients for which sequential samples were available the
status of P-gp and p53 did not vary. As in fact most
diagnoses of locally advanced breast cancer were based on
cytological needle aspirates, not enough material was
available to perform immunohistochemical studies in about
50% of them before the start of neoadjuvant chemotherapy.
Therefore we used post-chemotherapy P-gp/p53 tumour
status to analyse clinical outcome in a larger group of
locally advanced breast cancers. To confirm the prognostic
impact of P-gp+/p53+ tumour status to be independent of
selective pressure by chemotherapy, we also performed
survival analysis in a group of chemotherapy-naive patients.
Indeed, P-gp+/p53+ tumour status appeared to have
prognostic value, both by univariate and multivariate
analysis, although less strong than in the group of locally
advanced breast cancers only.
In conclusion, these findings demonstrate that nuclear p53
accumulation is often associated with MDR] gene expression
in primary breast cancer, and suggest that co-expression ofP-
gp and mutant p53 belongs to a series of genetic events,
resulting in a more aggressive phenotype, drug resistance, and
poor prognosis.
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